Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$9.96
-3.8%
$10.18
$9.20
$14.63
$1.21B1.131.71 million shs1.29 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$17.35
-0.6%
$19.35
$16.67
$22.00
$1.10B0.4764,988 shs534,757 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
-3.2%
$1.41
$1.11
$2.04
$1.24B1.52.54 million shs2.05 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.31
-2.6%
$4.68
$3.81
$5.59
$322.04M0.74522,378 shs556,901 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
-3.77%-1.39%+2.47%-5.86%-5.95%
Innoviva, Inc. stock logo
INVA
Innoviva
-0.57%-0.74%-12.68%-7.57%-11.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-3.21%-3.21%+7.09%+11.85%+0.67%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-2.57%-2.21%+18.53%+12.03%+18.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$9.96
-3.8%
$10.18
$9.20
$14.63
$1.21B1.131.71 million shs1.29 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$17.35
-0.6%
$19.35
$16.67
$22.00
$1.10B0.4764,988 shs534,757 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
-3.2%
$1.41
$1.11
$2.04
$1.24B1.52.54 million shs2.05 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.31
-2.6%
$4.68
$3.81
$5.59
$322.04M0.74522,378 shs556,901 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
-3.77%-1.39%+2.47%-5.86%-5.95%
Innoviva, Inc. stock logo
INVA
Innoviva
-0.57%-0.74%-12.68%-7.57%-11.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-3.21%-3.21%+7.09%+11.85%+0.67%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-2.57%-2.21%+18.53%+12.03%+18.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.20
Hold$24.33144.31% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
2.71
Moderate Buy$37.60116.71% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.50
Moderate Buy$2.6373.84% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.67
Moderate Buy$16.50210.73% Upside

Current Analyst Ratings Breakdown

Latest VNDA, OPK, DVAX, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/8/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2025
Innoviva, Inc. stock logo
INVA
Innoviva
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$17.00
9/30/2025
Innoviva, Inc. stock logo
INVA
Innoviva
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$17.00
9/27/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$277.25M4.21$0.15 per share65.36$4.54 per share2.19
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.05$3.41 per share5.09$11.03 per share1.57
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.68$0.07 per share22.68$2.00 per share0.76
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.58N/AN/A$9.24 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.46N/A20.33N/A-16.67%5.10%3.00%11/6/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M$0.3155.9711.19N/A10.44%18.67%9.92%11/5/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.25N/AN/AN/A-26.68%-13.17%-8.28%11/6/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%11/5/2025 (Estimated)

Latest VNDA, OPK, DVAX, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.14N/AN/AN/A$94.00 millionN/A
11/6/2025Q3 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.03N/AN/AN/A$165.74 millionN/A
11/5/2025Q3 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.46N/AN/AN/A$91.31 millionN/A
11/5/2025Q3 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.38N/AN/AN/A$58.73 millionN/A
8/7/2025Q2 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.12$0.14+$0.02$0.14$87.55 million$95.44 million
8/6/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.57$0.77+$0.20$0.77$87.10 million$100.28 million
7/31/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.12-$0.19-$0.07-$0.19$165.74 million$156.80 million
7/31/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.45
6.65
6.01
Innoviva, Inc. stock logo
INVA
Innoviva
0.36
2.64
2.44
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
3.41
3.02
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.25
3.23

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.27 million113.77 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10063.02 million61.60 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.78 million399.35 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29059.09 million53.18 millionOptionable

Recent News About These Companies

Vanda Pharmaceuticals Reaches Agreement with FDA
Vanda wins appeals court fight over FDA jet lag ruling

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$9.96 -0.39 (-3.77%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$9.72 -0.24 (-2.36%)
As of 10/10/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva stock logo

Innoviva NASDAQ:INVA

$17.35 -0.10 (-0.57%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$17.26 -0.09 (-0.52%)
As of 10/10/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.51 -0.05 (-3.21%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.01 (+0.66%)
As of 10/10/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$5.31 -0.14 (-2.57%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$5.31 0.00 (0.00%)
As of 10/10/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.